logo
Kerala Reports Second Suspected Nipah Virus Death, 543 Under Surveillance

Kerala Reports Second Suspected Nipah Virus Death, 543 Under Surveillance

NDTV17 hours ago
Palakkad:
A 57-year-old man from Palakkad district in Kerala, who died on July 12, is suspected to have been infected with the Nipah virus, prompting the government to ramp up contact tracing and field-level surveillance in the area.
The man had been undergoing treatment at a private hospital in this northern district.
His samples were tested at Manjeri Medical College, where the result came back positive for Nipah, Health Minister Veena George said in a statement.
She added that the government is awaiting confirmation from the National Institute of Virology in Pune.
This is the second Nipah-related death reported in Kerala in recent days.
A native of Malappuram had recently died from the infection, while another patient from Palakkad district remains hospitalised.
In response to the fresh suspected case, the government has ramped up contact tracing and field-level surveillance in the area.
A list of 46 people who came into contact with the patient has been drawn up.
CCTV footage and mobile tower location data have been used to help identify those on the contact list.
A detailed route map of the patient's recent movements has been prepared, along with a family tree to trace close contacts.
Health teams are now carrying out fever surveillance in the region to detect any possible symptoms in others.
"Field teams have been strengthened, and all available data is being used to monitor the situation," George said.
Further steps will be taken once confirmation is received from the National Institute of Virology in Pune.
The minister has also instructed officials to step up the response team, considering the seriousness of the case.
Authorities have urged people in Palakkad and Malappuram districts to avoid unnecessary visits to hospitals, especially under the current circumstances.
Visits to friends or relatives receiving treatment should be strictly limited, officials said. Only one person is allowed to accompany a patient as a bystander.
Both healthcare workers and those coming to the hospital, including patients and their companions, are required to wear masks at all times, an official release said.
Meanwhile, the health minister also issued a Nipah alert to hospitals across six districts.
The advisory has been sent to medical facilities in Palakkad, Malappuram, Kozhikode, Kannur, Wayanad, and Thrissur. Hospitals have been directed to report any patients presenting with fever and symptoms resembling Nipah, including encephalitis and high-grade fever, the minister's office said.
According to the WHO, Nipah virus is a zoonotic disease that spreads from animals to humans and can also be transmitted through contaminated food or via direct human-to-human contact.
The Nipah virus contact list now includes a total of 543 people. Of these, 46 individuals are linked to the newly confirmed case, it said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Int'l AIDS forum kicks off in Rwanda's capital
Int'l AIDS forum kicks off in Rwanda's capital

United News of India

time2 hours ago

  • United News of India

Int'l AIDS forum kicks off in Rwanda's capital

Kigali, July 14 (UNI) The 13th International AIDS Society (IAS) Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. The event, themed "Breakthroughs amid Crisis: the Future of HIV Innovation," has convened about 4,000 participants, including global leaders, researchers, scientists, and civil society members. Speaking at the conference, Rwandan Minister of Health Sabin Nsanzimana said that Rwanda's experience in the HIV response over the past few decades demonstrates what is possible when countries prioritize people-centered approaches and invest in strategic partnerships. "We have better tools for prevention and treatment. We have better ways to engage our communities to fight stigma and discrimination, and better integration within our systems. This means we can not only achieve HIV control, but we also need to strengthen our health systems," he added. IAS President Beatriz Grinsztein underlined new World Health Organization (WHO) guidelines, groundbreaking licensing agreements, and promising research as signs that long-acting HIV prevention and treatment options are becoming more feasible for widespread use. "Our next challenge is clear: leaders must commit the funding and resources needed to integrate these scientific advances into health systems quickly and equitably so that people everywhere can benefit from these life-changing options," Grinsztejn emphasized. At the event, the WHO issued a statement announcing new guidelines that recommend using injectable lenacapavir twice a year as an additional pre-exposure prophylaxis option for HIV prevention -- a landmark policy action that could help reshape the global HIV response. "While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," WHO Director-General Tedros Adhanom Ghebreyesus is quoted as saying in the statement. The IAS Conference on HIV Science is recognized as the world's most influential meeting on HIV research and its applications. Its 2025 edition, which runs until Thursday, features hundreds of sessions and presentations focused on translating scientific breakthroughs into real-world impact, with a particular emphasis on solutions for regions and populations most affected by HIV. UNI XINHUA GNK

WHO recommends Gilead's twice-yearly injection for HIV prevention
WHO recommends Gilead's twice-yearly injection for HIV prevention

Economic Times

time2 hours ago

  • Economic Times

WHO recommends Gilead's twice-yearly injection for HIV prevention

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the U.S. health regulator approved the drug, giving patients new hope of interrupting virus transmission. The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care. "While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus, WHO Director-General. The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist. These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.

WHO recommends Gilead's twice-yearly injection for HIV prevention
WHO recommends Gilead's twice-yearly injection for HIV prevention

Time of India

time4 hours ago

  • Time of India

WHO recommends Gilead's twice-yearly injection for HIV prevention

The World Health Organization on Monday recommended Gilead 's lenacapavir , a twice-yearly injection, as a tool to prevent HIV infection . The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the U.S. health regulator approved the drug, giving patients new hope of interrupting virus transmission. The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo "While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus , WHO Director-General. The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist. Live Events These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents. WHO has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly procedures. Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store